Artemisinin Combination Therapy Market Insights and Emerging Trends by 2027
Wilmington, Delaware, United States, Transparency Market Research Inc. – The conventional low-priced mainstay drugs for the treatment of malaria, sulphadoxine-pyrimethamine (SP) and chloroquine (CQ), are witnessing a decline in sales, as they are becoming comparatively ineffective. During the last two decades in Asia, the issue has become a major concern. This has resulted in the adoption of artemisinin (derived from the Chinese herb Artemisia annua) in Africa as a standard treatment.
Read Report Overview - https://www.transparencymarketresearch.com/artemisinin-combination-therapy-market.html
It helped in setting a milestone for the artemisinin combination therapy market. The herb has been used to treat fevers and malaria for more than 2000 years. The World Health Organization (WHO) has adopted artemisinin-based combination therapy (ACTs) as the first-line treatment for plasmodium falciparum malaria.
As a combination therapy, it has demonstrated superiority to other drugs because of its ability to wipe out parasites and its life cycle stages faster. Its use with cancer transferrin to cure cancer is also adding value to the artemisinin combination therapy market.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68096
Triple ACTs (TACTs) combine with artemisinin and two other existing partner drugs to work effectively as stop-gap therapy for the treatment of multidrug-resistant malaria. It will be used till the arrival of new antimalarial drugs. TACTs are secure, competent, well-accepted, and economical. This artemisinin combination therapy is likely to gain wider acceptance among the target consumers. The barriers in the deployment should be identified and stakeholders should make efforts to overcome them, which will new growth avenues in artemisinin combination therapy market.
Artemisinin Combination Therapy Market Introduction
Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of plasmodium parasites in the blood of malaria patients. The WHO recommends artemisinin combination therapies (ACTs) as the first line of treatment for uncomplicated plasmodium falciparum malaria and as the second line of treatment for chloroquine-resistant P. vivax malaria.
This therapy combines an artemisinin derivative along with a partner drug, wherein artemisinin aids in reducing the number of parasites and the partner drug eliminates the remaining parasites. Efficacy of the treatment is determined by the drug combined with artemisinin, such as artesunate-mefloquine, dihydroartemisinin–piperaquine, and artemether-lumefantrine.
Falciparum malaria was one of the most common lethal infections which was treated with chloroquine and sulfadoxine-pyrimethamine. However, these drugs are not effective as treatment primarily in the tropical regions owing to the resistance developed against these drugs. According to the Medicines Malaria Venture (MMV), over 445,000 deaths were reported in 2016 due to malaria. The globally rising malaria endemic and the changing climatic conditions would contribute to the trend aiding in the artemisinin combination therapy market growth.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=68096
Artemisinin Combination Therapy Market- Competitive Landscape
The strategies adopted by the market players to enhance their market position include indication extension, focus on geographic expansion, and research & development. The national funding allocations, as announced by the Global Fund for 2018-2020, report that the funding available for the promotion of malaria programs is around US$1 billion.
Novartis AG
Novartis AG, established in 1895, is engaged in research, development, manufacturing and marketing of healthcare products across a range of areas, including neuroscience, ophthalmology, immunology, hepatology, respiratory, cardiology, dermatology, and cardio metabolic.
Sanofi
Sanofi, a leading pharmaceutical company is engaged in the manufacturing of prescription pharmaceuticals and vaccines. It is engaged in the development of cardiovascular, metabolic disorder, central nervous system (CNS), oncology, and thrombosis drugs and medicines.
Ipca Laboratories Ltd.
Ipca Laboratories is an Indian pharmaceutical company engaged in the manufacturing of over 350 formulations and 80 APIs for a range of therapeutic indications. According to the company, it is the market leader in India for anti-malarials with a market share of over 34% in 2018.
Artemisinin Combination Therapy Market - Dynamics
Growing malaria endemic
Malaria is a major health concern in endemic countries such as Sudan, wherein over 75% of the population is at the risk of acquiring the disease. Moreover, the widespread presence of chloroquine-resistant strains of P. falciparum in the malaria endemic countries makes artemisinin combination therapy the preferred choice of treatment. This is projected to fuel the growth of the artemisinin combination therapy market.
Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=68096
Increase in the procurement of ACT treatment courses
Increase in access to ACTs in the malaria-endemic countries contributes to the rising success in reducing the global malaria burden. According to the WHO, over 2.7 billion ACT treatment courses were procured by global countries between 2010 and 2017. Moreover, over 62% of these procurements were made by the public sector. Strong pipeline for the development of new anti-malarial drugs and launch of newer artemisinin combinations for the treatment of malaria boost to the growth of the global artemisinin combination therapy market.
Challenges related to the availability of raw materials
Challenges pertaining to the availability of intermediate products and raw materials in the production of artemisinin-based combination therapies from agricultural sources are expected to restrain the global artemisinin combination therapy market. Furthermore, volatility in the artemisinin market leading to concerns over supply tightening could create significant risks to patients and market participants.
More Trending Reports by Transparency Market Research –
Bioinformatics Market: The global bioinformatics market is expected to reach the value of US$ 44.9 Bn by the end of 2028 and to expand at a CAGR of 5.9% from 2021 to 2028.
Taurine Market: The global taurine market is expected to reach the value of US$ 0.3 Bn by the end of 2031. It is estimated to expand at a CAGR of 5.3% from 2021 to 2031.
Telehealth Market: The global telehealth market is expected to reach the value of US$ 15 Bn by the end of 2028. It is estimated to expand at a CAGR of 7% from 2021 to 2028.
Medical Device Technologies Market: The global medical device technologies market is expected to reach the value of US$ 662.7 Bn by the end of 2028.
Forensic Technologies Market: The global forensic technologies market is expected to reach the value of US$ 87.4 Bn by the end of 2028.
Microbiology Culture Market: The U.S. microbiology culture market is expected to reach the value of US$ 5.4 Bn by the end of 2031.
Nanomedicine Market: The global nanomedicine market is expected to reach the value of US$ 512.5 Bn by the end of 2028 and to expand at a CAGR of 12.6% from 2021 to 2028.
Smart Medical Devices Market: The global smart medical devices market is expected to reach the value of US$ 70.1 Bn by the end of 2028.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com